Compare Franco-Nevada Corporation (FNV) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Franco-Nevada Corporation vs TransMedics Group Inc — how do they compare? Franco-Nevada Corporation trades at $236.47 (market cap $45.36B), while TransMedics Group Inc trades at $75.5 (market cap $2.62B). The key difference: Franco-Nevada Corporation is far larger — about 17.3× TransMedics Group Inc's market cap, and Franco-Nevada Corporation pays a 0.75% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Franco-Nevada Corporation for 0 Days and TransMedics Group Inc for 24 Days on average.
| FNV | TMDX | |
|---|---|---|
Market Cap | $45.36B | $2.62B |
Volume | 787,841 | 891,435 |
Sector | Basic Materials | Health |
52-Week High | $280.82 | $150.42 |
52-Week Low | $183.97 | $61.99 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $44.34B | $3.01B |
Dividend Yield | 0.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Franco-Nevada (FNV) trades at $243.85, showing a slight decline of 0.77% over the past day. The stock is positioned neutrally from a technical perspective, with key support near $242 and resistance at $246. Fundamentally, the company exhibits strong profitability with a net income margin of 63.79% and has beaten earnings expectations in two of the last three quarters. Recent news highlights portfolio expansion, including a significant investment in the Bullabulling Gold Project and positive developments regarding the potential restart of the Cobre Panama mine.
The outlook for FNV is supported by analyst consensus, with a price target of $275 suggesting potential upside. Key opportunities include revenue growth from new projects and high profit margins. Risks involve execution on new investments, commodity price volatility, and geopolitical factors affecting mining operations. The balanced analyst rating split indicates cautious optimism for future performance.
TransMedics Group (TMDX) trades at $79.135, up 1.23% on the day, but faces a bearish technical signal with recent earnings misses in Q1 and Q2 2026. The company maintains strong profitability with a 58.69% gross margin and 22.69% net margin, though net income is projected to decline in 2026. Recent news highlights insider buying and CFO appointment, but also ongoing legal investigations into fiduciary duties.
The stock presents a mixed outlook; analyst consensus is bullish with a $99.63 price target, but risks include margin pressure from heavy investment and legal overhangs. Upside hinges on execution against guidance, while downside is cushioned by solid cash flow and institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Franco-Nevada Corporation
Franco-Nevada Corporation is a royalty and streaming company that finances mining and energy projects in exchange for royalty payments or the right to purchase output at set prices, holding a diversified portfolio across Precious Metals, Other Mining, and Energy (oil, gas, and natural gas liquids).
Read more on FNV →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
